Neophyte.

This NCDB look at treatment trends for advanced ovarian cancer indicates there are a lot of newcomers embracing the paradigm of neoadjuvant chemo for stage IIIC-IV disease, up from 18% in 2006 to 45% in 2016. Unfortunately, a number of large randomized trials published in the last few years demonstrate no advantage to this strategy, supported by the fact the use of neoadjuvant chemo among this cohort was sadly associated with no improvement in survival outcomes. | Knisely, JAMA Netw Open 2020

Comments

Popular Posts